-Dow Jones
SVB Leerink Maintains Market Perform on Genmab, Lowers Price Target to $30
SVB Leerink analyst Jonathan Chang maintains Genmab (NASDAQ:GMAB) with a Market Perform and lowers the price target from $39 to $30.
Related Posts
Bernstein Upgrades Alibaba Group Holding to Outperform, Raises Price Target to $130
Bernstein analyst Robin Zhu upgrades Alibaba Group Holding (NYSE:BABA) from Market Perform to Outperform and raises the price target from $115 to $130.
Disney to be First Client at 18 Sound Stage Shinfield Studios in U.K
-Variety
https://variety.com/2021/film/news/disney-shinfield-studios-uk-1235131847/
Ra Medical Systems Q2 EPS $(1.28), Adj. EBITDA Loss $6.1M, Sales $1.00M Beat $990.00K Estimate
Ra Medical Systems (NYSE:RMED) reported quarterly losses of $(1.28) per share. The company reported quarterly sales of $1.00 million which beat the analyst consensus estimate of $990.00 thousand by 1.01 percent.